echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > BMJ Open: Regular blood tests can be used for screening for advanced liver disease

    BMJ Open: Regular blood tests can be used for screening for advanced liver disease

    • Last Update: 2021-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    With the improvement of living standards, the prevalence of metabolic liver disease, including non-alcoholic fatty liver disease and alcohol-related liver disease, is increasing, which eventually leads to an increase in end-stage liver disease (liver failure, cirrhosis, liver cancer).
    data show that hundreds of millions of people worldwide are affected by liver disease.
    as many as 7 million people in China suffer from cirrhosis, with 460,000 new cases of liver cancer each year.
    guidelines recommend strengthening early detection of liver disease and its treatment in primary care to identify early cirrhosis.
    a recent study published in the journal BMJ Open, researchers developed a CIRRUS algorithm that predicts advanced liver disease with an accuracy of about 90 percent.
    In the study, researchers performed a Logistic regression analysis of blood data routinely collected by the University Hospital of Southampton (UHS) information system and based it on the AdvLD model, and then validated predictions of first severe liver events (SLE) in two queues of 394,253 (UHS: primary and secondary care) and 183,045 (CHIE: primary care care and health information).
    , UHS and CHIE validation queues recorded 3,044 cases (0.8%) and 1,170 (0.6%) SLE, respectively.
    in the UHS queue, CIRRUS predicts SLE for the first time in five years, with a continuous curve area of 0.90 (0.89 to 0.91) and a 0.88 (0.87 to 0) area under the continuous curve. .89) (dark red, red, amber, green grade); CHIE queue AAUC is 0.84 (0.82 to 0.86) and 0.83 (0.81 to 0.85).
    In patients with specific liver risk factors (alcohol, diabetes, viral hepatitis), the crimson/red threshold predicts first SLE, UHS and CHIE queue sensitivity of 72% and 59%, specificity of 87% and 93%, positive predictions of 26% and 18%, and negative predictions of 98% and 99%.
    "This new CIRRUS algorithm can be used in routine blood tests," said the researchers, who analyzed the area under the curve of the validation dataset 1 (UHS) and validation dataset 2 (CHIE) to predict the index's severe liver event (SLE) test over a five-year date.
    most cases, the liver can recover even if late-stage patients can address the cause by changing their lifestyle, stopping drinking or losing weight.
    all of us are plagued by a coronavirus pandemic, we cannot ignore the causes of other potentially preventable deaths and serious diseases.
    detect serious liver disease early through routine blood test data, which may reduce emergency hospitalization and serious health conditions.
    " In short, cirrhosis is a silent killer, and the CIRRUS algorithm is designed to identify the risk of advanced liver disease based on routine blood tests (albumin, creatinine, bilirin, average red blood cell volume, sodium, platelet count, protein).
    unlike most diagnostic liver algorithms, the CIRRUS model was created using data sets from primary and secondary health care patients and is more suitable for screening for liver disease outside of secondary health care hepatology.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.